SBIR-STTR Award

COVID-19: High Efficiency SARS-CoV-2 Virus Aerosol Sampling and Sensing
Award last edited on: 1/21/2022

Sponsored Program
STTR
Awarding Agency
NIH : NIAID
Total Award Amount
$262,802
Award Phase
1
Solicitation Topic Code
855
Principal Investigator
Patricia Bea Keady

Company Information

Aerosol Devices Inc

430 North College Avenue Suite 430
Fort Collins, CO 80524
   (970) 744-3244
   info@aerosoldevices.com
   www.aerosoldevices.com

Research Institution

----------

Phase I

Contract Number: 1R41AI157347-01A1
Start Date: 7/6/2021    Completed: 6/30/2022
Phase I year
2021
Phase I Amount
$262,802
As the current COVID-19 pandemic has demonstrated, aerosolized pathogens such as SARS-CoV-2 can spread explosively if not quickly detected. Early detection of these airborne pathogens can help control out- breaks, particularly within vulnerable populations in densely populated spaces including assisted living facili- ties, places of worship, military installations, hospitals, and prisons. To date, most studies of aerosolized SARS-CoV-2 use filter collection followed by laboratory analysis of viral RNA. While this gives a general indica- tion of viral RNA levels in an environment, filters collect both infectious and non-infectious viruses and damage them through mechanical stress and desiccation, making it difficult to determine the infective fraction of the col- lected viruses. Further, current filter analysis methods require time-consuming nucleic acid extraction and am- plification techniques not suitable to rapid, point-of-care monitoring. Therefore, there is an urgent need for in- struments that can detect intact viruses at the point-of-care. We propose to develop a sensitive, direct reading, bioaerosol detection platform that can quantify specific air- borne pathogens at the point of collection. Furthermore, if a positive result is identified, the sample can be taken to a central laboratory for additional molecular analysis and infectivity testing. This device will integrate the bioaerosol collection technology developed at Aerosol Devices Inc. (ADev) with virus detection technology from Colorado State University (CSU). Using gentle condensation-growth capture that mimics the human lung, the ADev sampler will be the front-end of the platform, concentrating intact, viable virus particles into a small liquid volume. With >90% collection efficiency for particle sizes <10 nm up to 10 µm, ADev samplers uniformly collect all inhalable SARS-CoV-2 particles whether originating from cough droplets (>5 µm), smaller particles exhaled during breathing or talking (<5 µm), or shed as individual virus particles (~120 nm). CSU Professors Henry, Dandy, and Geiss are developing innovative, inexpensive electrochemical biosensors to rapidly detect intact viruses in liquid samples. By synergizing these robust sensors with the ADev aerosol sampler, we will produce a system that can detect and quantify ultra-low concentrations of viral pathogens in near real-time. In this phase I STTR project, we will adapt our commercial aerosol-into-liquid collector to incorporate CSU’s biosensors. Specific aims for the ADev sampler include extending sampling time to 24 h to enhance limits of detection, increasing volumetric sampling rate to improve temporal resolution, selecting materials compatible with VHP decontamination and optimizing the system to reduce size, weight, power consumption and cost. Specific aims for the biosensor include modifying electrodes to detect SARS-CoV-2 particles with high sensitiv- ity and selectivity, adapting our current electrode configuration to work with the ADev sampling vial, and testing the system with infectious SARS-CoV-2 in our BSL-3 laboratory. Our immediate focus is SARS-CoV-2, but this technology can be adapted in Phase II to detect any airborne pathogen (e.g., Influenza, B. anthracis, etc.). Public Health Relevance Statement Project Narrative Transmission of SARS-CoV-2 as aerosol is a major contributor to the rapid spread of COVID-19. There is an urgent need for tools that provide early warning of respiratory exposure to airborne virus particles for vulnerable populations at the point-of-care (e.g., nursing homes, airports, prisons or public transportation) to facilitate timely intervention and limit the spread of the disease. In this project, we will synergize our robust commercial ADev condensation growth sampler with CSU’s unique virus detection technology to develop an aerosol sampling system that collects and concentrates intact virus particles for near-real-time detection with an integrated ultra-sensitive electrochemical biosensor.

Project Terms:
Aerosols ; Air ; Antibodies ; Breathing ; Respiratory Aspiration ; Respiratory Inspiration ; inspiration ; Bacillus anthracis ; B anthracis ; B. anthracis ; anthracis ; Bacteria ; Bordetella pertussis ; B pertussis ; B. pertussis ; H Pertussis ; H. Pertussis ; Haemophilus pertussis ; Buffers ; Colorado ; Coughing ; Decontamination ; Desiccation ; Dessication ; Disease ; Disorder ; Disease Outbreaks ; Outbreaks ; Electrodes ; Environment ; Future ; Goals ; Growth ; Generalized Growth ; Tissue Growth ; ontogeny ; Health care facility ; Health Facilities ; Healthcare Facility ; care facilities ; Health Personnel ; Health Care Providers ; Healthcare Providers ; Healthcare worker ; health care personnel ; health care worker ; health provider ; health workforce ; healthcare personnel ; medical personnel ; treatment provider ; Hospitals ; Human ; Modern Man ; Influenza ; Grippe ; Laboratories ; Long-Term Care ; extended care ; longterm care ; Lung ; Lung Respiratory System ; pulmonary ; Measles ; Rubeola ; morbilli ; Methods ; Military Personnel ; Armed Forces Personnel ; Military ; military population ; Nucleic Acids ; Nursing Homes ; nursing home ; Particle Size ; Patients ; Play ; Prisons ; Reading ; RNA ; Non-Polyadenylated RNA ; RNA Gene Products ; Ribonucleic Acid ; viral RNA ; virus RNA ; Spectrum Analysis ; Spectroscopy ; Spectrum Analyses ; Mechanical Stress ; Technology ; Testing ; Time ; Transportation ; Universities ; Virion ; Virus Particle ; virology ; Virus ; Weight ; Work ; Social Impacts ; electric impedance ; Electrical Impedance ; Impedance ; Tube ; base ; Label ; sensor ; Vial device ; Vial ; improved ; Surface ; Phase ; Ensure ; Individual ; Recovery ; Collaborations ; fluid ; liquid ; Liquid substance ; Exposure to ; tool ; instrument ; Hour ; Exhaling ; Respiratory Expiration ; Exhalation ; Techniques ; System ; respiratory ; early detection ; Early Diagnosis ; particle ; condensation ; Physical condensation ; RT-PCR ; RTPCR ; reverse transcriptase PCR ; Reverse Transcriptase Polymerase Chain Reaction ; professor ; biological sensor ; Biosensor ; sterile ; Sterility ; Structure ; economic impact ; General Public ; General Population ; Devices ; Reporting ; Sampling ; assisted living ; assistive living ; assistive living facilities ; Assisted Living Facilities ; Abate ; Intervention Strategies ; interventional strategy ; Intervention ; vulnerable group ; Vulnerable Populations ; Influenza B ; Influenza Viruses Type B ; Orthomyxoviruses Type B ; Influenza B Virus ; Molecular Interaction ; Binding ; preventing ; prevent ; Detection ; Molecular Analysis ; Resolution ; Collection ; Small Business Technology Transfer Research ; STTR ; Monitor ; transmission process ; Transmission ; point of care ; pandemic disease ; pandemic ; cost ; viral detection ; virus detection ; Outcome ; pathogen ; Consumption ; innovation ; innovate ; innovative ; aerosolized ; prototype ; operation ; temporal measurement ; temporal resolution ; time measurement ; Bluetooth ; pathogenic virus ; viral pathogen ; virus pathogen ; COVID-19 ; COVID19 ; CV-19 ; CV19 ; corona virus disease 2019 ; coronavirus disease 2019 ; 2019-nCoV ; 2019 novel corona virus ; 2019 novel coronavirus ; COVID-19 virus ; COVID19 virus ; CoV-2 ; CoV2 ; SARS corona virus 2 ; SARS-CoV-2 ; SARS-CoV2 ; SARS-associated corona virus 2 ; SARS-associated coronavirus 2 ; SARS-coronavirus-2 ; SARS-related corona virus 2 ; SARS-related coronavirus 2 ; SARSCoV2 ; Severe Acute Respiratory Distress Syndrome CoV 2 ; Severe Acute Respiratory Distress Syndrome Corona Virus 2 ; Severe Acute Respiratory Distress Syndrome Coronavirus 2 ; Severe Acute Respiratory Syndrome CoV 2 ; Severe Acute Respiratory Syndrome-associated coronavirus 2 ; Severe Acute Respiratory Syndrome-related coronavirus 2 ; Severe acute respiratory syndrome associated corona virus 2 ; Severe acute respiratory syndrome corona virus 2 ; Severe acute respiratory syndrome coronavirus 2 ; Severe acute respiratory syndrome related corona virus 2 ; Wuhan coronavirus ; coronavirus disease 2019 virus ; hCoV19 ; nCoV2 ; COVID-19 pandemic ; COVID crisis ; COVID epidemic ; COVID pandemic ; COVID-19 crisis ; COVID-19 epidemic ; COVID-19 global health crisis ; COVID-19 global pandemic ; COVID-19 health crisis ; COVID-19 public health crisis ; COVID19 crisis ; COVID19 epidemic ; COVID19 global health crisis ; COVID19 global pandemic ; COVID19 health crisis ; COVID19 pandemic ; COVID19 public health crisis ; SARS-CoV-2 epidemic ; SARS-CoV-2 global health crisis ; SARS-CoV-2 global pandemic ; SARS-CoV-2 pandemic ; SARS-CoV2 epidemic ; SARS-CoV2 pandemic ; SARS-coronavirus-2 epidemic ; SARS-coronavirus-2 pandemic ; Severe Acute Respiratory Syndrome CoV 2 epidemic ; Severe Acute Respiratory Syndrome CoV 2 pandemic ; Severe acute respiratory syndrome coronavirus 2 epidemic ; Severe acute respiratory syndrome coronavirus 2 pandemic ; corona virus disease 2019 epidemic ; corona virus disease 2019 pandemic ; coronavirus disease 2019 crisis ; coronavirus disease 2019 epidemic ; coronavirus disease 2019 global health crisis ; coronavirus disease 2019 global pandemic ; coronavirus disease 2019 health crisis ; coronavirus disease 2019 pandemic ; coronavirus disease 2019 public health crisis ; coronavirus disease crisis ; coronavirus disease epidemic ; coronavirus disease pandemic ; severe acute respiratory syndrome coronavirus 2 global health crisis ; severe acute respiratory syndrome coronavirus 2 global pandemic ; SARS-CoV-2 spike protein ; 2019-nCoV S protein ; 2019-nCoV spike glycoprotein ; 2019-nCoV spike protein ; COVID-19 S protein ; COVID-19 spike glycoprotein ; COVID-19 spike protein ; COVID19 S protein ; COVID19 spike glycoprotein ; COVID19 spike protein ; SARS-CoV-2 S protein ; SARS-CoV-2 spike glycoprotein ; SARS-CoV2 S protein ; SARS-CoV2 spike glycoprotein ; SARS-CoV2 spike protein ; Severe acute respiratory syndrome coronavirus 2 S protein ; Severe acute respiratory syndrome coronavirus 2 spike glycoprotein ; Severe acute respiratory syndrome coronavirus 2 spike protein ; coronavirus disease 2019 S protein ; coronavirus disease 2019 spike glycoprotein ; coronavirus disease 2019 spike protein ; respiratory pathogen ; lung pathogen ; pulmonary pathogen ; COVID-19 detection ; COVID19 detection ; SARS-CoV-2 detection ; coronavirus disease 2019 detection ; detect COVID-19 ; detect COVID19 ; detect SARS-CoV-2 ; detect severe acute respiratory syndrome coronavirus 2 ; severe acute respiratory syndrome coronavirus 2 detection ; SARS-CoV-2 antibody ; COVID-19 antibody ; SARS-CoV2 antibody ; antibody against COVID-19 ; antibody against SARS-CoV-2 ; antibody against SARS-CoV2 ; antibody against coronavirus disease 2019 ; antibody against severe acute respiratory syndrome coronavirus 2 ; antibody to COVID-19 ; antibody to SARS-CoV-2 ; antibody to SARS-CoV2 ; antibody to coronavirus disease 2019 ; antibody to severe acute respiratory syndrome coronavirus 2 ; coronavirus disease 2019 antibody ; severe acute respiratory syndrome coronavirus 2 antibody ; detection limit ; detection method ; detection procedure ; detection technique ; detection platform ; detection system ; SARS-CoV-2 transmission ; COVID-19 transmission ; COVID-19 virus transmission ; coronavirus disease 2019 transmission ; coronavirus disease 2019 virus transmission ; severe acute respiratory syndrome coronavirus 2 transmission ; transmitted COVID-19 ; transmitted SARS-CoV-2 ; transmitted coronavirus disease 2019 ; transmitted severe acute respiratory syndrome coronavirus 2 ; SARS-CoV-2 infection ; COVID-19 infection ; COVID19 infection ; SARS-CoV2 infection ; Severe acute respiratory syndrome coronavirus 2 infection ; coronavirus disease 2019 infection ; infected with COVID-19 ; infected with COVID19 ; infected with SARS-CoV-2 ; infected with SARS-CoV2 ; infected with coronavirus disease 2019 ; infected with severe acute respiratory syndrome coronavirus 2 ;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----